¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"principal component analysis"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • principal reaction
    ÁÖ¹ÝÀÀ
  • principal sensory nucleus
    ÁÖ°¨°¢ÇÙ, À¸¶ä°¨°¢ÇÙ
  • quick component
    ºü¸¥¼ººÐ
  • solid component
    °íÇü¼ººÐ
  • series elastic component
    Á÷¿­Åº·Â¼ººÐ
  • slow component
    ´À¸°¼ººÐ
  • antigen analysis
    Ç׿øºÐ¼®
  • arterial blood gas analysis
    µ¿¸ÆÇ÷°¡½ººÐ¼®
  • activation analysis
    Ȱ¼ºÈ­ºÐ¼®, ¹æ»çÈ­ºÐ¼®
  • age-period cohort analysis
    ¿¬·É±â°£ÄÚȣƮºÐ¼®
  • analysis
    ºÐ¼®
  • birth cohort analysis
    Ãâ»ýÄÚȣƮºÐ¼®
  • clinical decision analysis
    ÀÓ»óÀÇ»ç°áÁ¤ºÐ¼®
  • clonal analysis
    Ŭ·ÐºÐ¼®
  • cluster analysis
    ¹«¸®ºÐ¼®
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • principal fiber
    À¸¶ä¼¶À¯
  • principal focus
    ÁÖÃÊÁ¡
  • principal meridian
    À¸¶ä³¯ÁÙ, ÁÖ¿ä°æ¼±
  • principal nucleolus
    À¸¶äÇÙ¼Òü
  • principal sensory nucleus
    ÁÖ°¨°¢ÇÙ
  • principal
    ÁÖ-, ÁÖ¿ä-
  • principal piece
    À¸¶äºÎºÐ, ÁֵȺκÐ
  • principal reaction
    ÁÖ¹ÝÀÀ
  • principal outer membrane protein
    Áֿܸ·´Ü¹éÁú
  • analysis
    ºÐ¼®
  • activation analysis
    Ȱ¼ºÈ­ºÐ¼®, ¹æ»çÈ­ºÐ¼®
  • age-period cohort analysis
    ¿¬·É±â°£ÄÚȣƮºÐ¼®
  • antigen analysis
    Ç׿øºÐ¼®
  • birth cohort analysis
    Ãâ»ýÄÚȣƮºÐ¼®
  • case analysis
    Áõ·ÊºÐ¼®
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • principal fiber
    À¸¶ä¼¶À¯
  • principal focus
    ÁÖÃÊÁ¡(ñ«õ¥ïÇ).
  • principal meridian
    ÁÖ°æ¼±
  • principal nucleolus
    À¸¶äÇÙ¼Òü
  • principal outer membrane protein (POMP)
    ÁÖ¿ä¿Ü¸·´Ü¹éÁú
  • principal part
    À¸¶äºÎºÐ
  • principal piece
    ÁֵȺκÐ
  • principal piece
    À¸¶äºÎºÐ
  • principal plane
    ÁÖ¸é(ñ«Øü).
  • principal point
    ÁÖÁ¡(ñ«ïÇ) ½ÃÃà(ãÊõî)ÀÇ .
  • principal point
    ÁÖÁ¡
  • principal quantum number
    ÁÖ¾çÀÚ¼ö(ñ«åÖ í­â¦).
  • principal reaction
    ÁÖ¹ÝÀÀ(ñ«Úãëë).
  • principal series
    ÁÖ°è¿­(̡˭Ëç).
  • principal strain
    ÁÖº¯Çü(ñ«Ü¨û¡).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • quick component
    ±Þ°Ý¼ººÐ(ÐáÌ­à÷ÝÂ).
  • secretory component
    ºÐºñ¼ººÐ
  • series elastic component
    Á÷·Äź·Â¼ººÐ(òÁ æê÷¥æ³à÷ÝÂ).
  • slow component
    ¿Ï¼­¼ººÐ(èÐßïà÷ÝÂ).
  • third component
    Á¦»ï¼ººÐ(ð¯ß²à÷ÝÂ).
  • thromboplastin plasma component
    Ç÷¼ÒÆÇ¼º Ç÷À强ºÐ(úìá³÷ùàõúìíìà÷ÝÂ).
  • inner principal layer
    ³»ÇÙÃþ.
  • principal axis
    ÁÖÃà(ñ«õî).
  • principal cell
    ÁÖ¼¼Æ÷(ñ«á¬øà).
  • principal cell
    À¸¶ä¼¼Æ÷
  • principal cell
    ÁÖ¼¼Æ÷(ñ«á¬øà).
  • principal fiber
    À¸¶ä¼¶À¯
  • principal focus
    ÁÖÃÊÁ¡(ñ«õ¥ïÇ).
  • principal meridian
    ÁÖ°æ¼±
  • principal nucleolus
    À¸¶äÇÙ¼Òü
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • double isotope dilution analysis
    ÀÌÁß µ¿À§¿ø¼Ò Èñ¼®ºÐ¼®(ì£ñìÔÒêÈêªáÈýüà·ÝÂà°)
  • elementary analysis
    ¿ø¼Ò ºÐ¼® (êªáÈÝÂà°)
  • elution analysis
    ¿ë¸® ºÐ¼® (éÁ×îÝÂà°)
  • end-group analysis
    Á¾´Ü±â ºÐ¼® (ðûÓ®ÐñÝÂà°)
  • fluctuation analysis
    ¿äµ¿ ºÐ¼®(èôÔÑÝÂà°)
  • gravimetric analysis
    ¹«°Ô ºÐ¼®(ÝÂà°)
  • inhibition analysis
    ÀúÇØºÐ¼®(îÁúªÝÂà°)
  • ionic mobility analysis
    À̿ À̵¿µµ(ì¹ÔÑÓø) ºÐ¼®(ÝÂà°)
  • isoelectric analysis
    µîÀüºÐ¼®(Ôõï³ÝÂà°)
  • isotope dilution analysis
    µ¿À§¿ø¼Ò Èñ¼®ºÐ¼®(ÔÒêÈêªáÈýüà·ÝÂà°)
  • isotopic dilution analysis
    µ¿À§¿ø¼Ò Èñ¼®ºÐ¼®(ÔÒêÈêªáÈýüà·ÝÂà°)
  • kinetic analysis
    ¹ÝÀÀ¼ÓµµºÐ¼®(ÚãëëáÜÓøÝÂà°)
  • methylation analysis
    ¸Þƿȭ(ûù)ºÐ¼®(ÝÂà°)
  • mobility shift analysis
    À̵¿µµ(ì¹ÔÑÓø)¿Å±è ºÐ¼®(ÝÂà°)
  • moving boundary analysis
    À̵¿°æ°è ºÐ¼®(ì¹ÔÑÌÑÍ£ÝÂà°)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • statistical analysis
    Åë°èÀûºÐ¼®
  • urine analysis
    ¿ä°Ë»ç
  • vector analysis
    ¹éÅͺм®
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
MEDPAR Medical Provider Analysis and Review; Medicare Provider Analysis and Review
MRA magnetic resonance angiography; main renal artery; marrow repopulation activity; medical record anal...
PCMO Principal Clinical Medical Officer
PI first meiotic prophase; isoelectric point; pacing impulse; package insert; pancreatic insufficiency;...
PMO postmenopausal osteoporosis; Principal Medical Officer
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
PC Principal cells
PND principal Neutralizing Determinant
PND principal neutralizing domain
PO principal olive
AC Aesthetic Component
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • binding displacement analysis
    °áÇÕ º¯À§ ºÐ¼®
  • bite analysis
    ±³ÇÕ ºÐ¼®
    ±³ÇÕ°£ °ü°è³ª ±× Ç¥½Ã¸¦ ºÐ¼®ÇÏ´Â °Í.
  • case analysis
    Áõ·Ê ºÐ¼®
  • character analysis
    ¼º°Ý ºÐ¼®
  • cluster analysis
    ±ÕÁÖ±º ºÐ¼®
  • computerized image analysis
    ÄÄÇ»ÅÍ ¿µ»ó ºÐ¼®
  • continuous flow blood analysis
    Áö¼Ó¼º À¯µ¿ Ç÷¾× ºÐ¼®
  • dietary analysis
    ½ÄÀÌ ºÐ¼®
  • dynamic mechanical analysis
    µ¿Àû ±â°èÀû ºÐ¼®
  • ego analysis
    ÀÚ¾Æ ºÐ¼®
  • electron beam microporbe analysis
    ÀüÀÚ±¤ ¹Ì¼¼ Žħ ¿ä¼Ò ºÐ¼®, ÀüÀÚ±¤ ¹Ì¼¼ Žħ ºÐ¼®
  • electron microprobe analysis
    ÀüÀÚ ¹Ì¼¼ Žħ
  • elementary analysis
    ¿ø¼Ò ºÐ¼®
    À¯±â È­ÇÕ¹°¿¡ ÇÔÀ¯µÇ¾î ÀÖ´Â ¿ø¼ÒÀÇ Á¾·ù¸¦ °áÁ¤Çϰųª, ºñÀ²À» °áÁ¤ÇÏ´Â ºÐ¼® ¹æ¹ý. ÀüÀÚ¸¦ Á¤¼º ¿ø¼Ò ºÐ¼®, ÈÄÀÚ¸¦ Á¤·® ¿ø¼Ò ºÐ¼®À̶ó°í ÇÑ´Ù. Á¤¼º ¿ø¼Ò ºÐ¼®, Áï ¿ø¼Ò °ËÃâ¹ý¿¡¼­´Â À¯±â È­ÇÕ¹°À» ±¸¼ºÇϰí ÀÖ´Â °¢ ¿ø¼Ò¿¡ µû¶ó ¿©·¯ °¡Áö ¹æ¹ýÀÌ »ç¿ëµÇÁö¸¸, ¸ðµÎ À¯±â È­ÇÕ¹°À» ºÐÇØÇÏ¿© °£´ÜÇÑ ¹«±â È­ÇÕ¹°·Î °ËÃâÇÑ´Ù. Á¤·® ¿ø¼Ò ºÐ¼®, Áï ÇÔÀ¯·®À» °áÁ¤ÇÏ´Â ¹æ¹ý¿¡´Â äÃëÇÏ´Â ½Ã·áÀÇ ¾ç¿¡ µû¶ó¼­ »ó·®¹ý
  • Enlow Analysis
    ¿£·Î¿ì ºÐ¼®
  • frequency analysis
    ÁÖÆÄ ¼ö ºÐ¼®
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
blood component transfusion The transfer of blood components such as erythrocytes, leukocytes, platelets, and plasma from a donor to a recipient or back to the donor. This process differs from the procedures undertaken in plasmapheresis and types of cytapheresis (plateletpheresis and leukapheresis) where, following the removal of plasma or the specific cell components, the remainder is transfused back to the donor.
(12 Dec 1998)
p18 component, aminoacyl tRNA synthetase <enzyme> Shares a protein motif with the beta and gamma subunits of eukaryotic elongation factor 1; amino acid sequence given in first source
Registry number: EC 6.1.1.-
Synonym: p18 aminoacyl-trna synthase
(26 Jun 1999)
granular component of nucleolus Area of nucleolus that appears granular in the electron microscope and contains 15nm diameter particles that are maturing ribosomes. In contrast to the pale staining and fibrillar areas.
(18 Nov 1997)
component <physiology> A constituent element or part, specifically in neurology, a series of neurons forming a functional system for conducting the afferent and efferent impulses in the somatic and splanchnic mechanisms of the body.
(05 Jan 1998)
component A, Rab geranylgeranyl transferase <chemical> Binds unprenylated rab1a and presents it to the catalytic component b; do not confuse with rep-1 from yeast; see also mrs6 protein
Synonym: rab escort protein, rab geranylgeranyltransferase component a, rep-1 protein, rab escort protein-1, choroideraemia gene product, chm gene product, mrs6 gene product
(26 Jun 1999)
component E, glutamate mutase <chemical> The large subunit of glutamate mutase; from clostridium tetanomorphum; has 485 amino acid residues; mw 53,708 da; has been sequenced
Synonym: mute gene product, clostridium, mute protein, clostridium
(26 Jun 1999)
component of complement Any one of the nine distinct protein units (designated C1 through C9 and distributed in the a, b, and g electrophoretic partitions of normal serum) that effect the immunological activities long associated with complement. C1 is a complex of three subunits: C1q, C1r, and C1s. C1q (overbar indicates "active form") activates proenzyme C1r to C1r which activates C1s to C1s (also known as C1 esterase), which converts proenzyme C2 to C2b and produces C4b from C4. C2b combines with C4b to form "classical-complement-pathway C3/C5 convertase" (also known as C3 convertase, C5 convertase, and C42). This enzyme cleaves C3 to C3a and C3b, and C5 to yield C5a and C5b, as does "alternative-complement-pathway C3/C5 convertase" (also known as proenzyme factor B, properdin factor B, C3 proactivator, and heat-labile factor). Complement factor I (also known as C3b or C3b/C4b inactivator) inactivates C3b and C4b by a different proteolytic cleavage. Several autosomal recessive disorders have been identified in which one or more of the complement components have been deficient or completely absent.
(05 Mar 2000)
component of force One of the factors from which a resultant force may be compounded or into which it may be resolved, one of the vectors into which a force may be resolved.
(05 Mar 2000)
component S, glutamate mutase <chemical> Component s of the coenzyme b12-dependent glutamate mutase from clostridium cochlearium; mw 15 kD; amino acid sequence given in first source
Synonym: glms gene product, muts gene product (clostridium)
(26 Jun 1999)
plasma thromboplastin component <chemical> Storage-stable blood coagulation factor acting in the intrinsic pathway. Its activated form, ixa, forms a complex with factor viii and calcium on platelet factor 3 to activate factor x to xa. Deficiency of factor ix results in christmas disease (haemophilia b).
Chemical name: Blood-coagulation factor IX
(12 Dec 1998)
habitat component <ecology> A single element (for example, velocity, depth, cover, etc.) of the habitat or environment in which a fish or other aquatic species or population may live or occur.
(09 Oct 1997)
secretory component <physiology> A glycoprotein found in a variety of external secretions (tears, bile, colostrum) usually complexed to secreted polymeric immunoglobulins (IgA or, less frequently IgM).
It is derived, by proteolytic cleavage, from the polymeric immunoglobulin receptor (receptors, polymeric immunoglobulin) and probably functions to protect the immunoglobulins from proteolysis in the secretions.
(12 Dec 1998)
secretory component of IgA <immunology, protein> A polypeptide chain of about 60 kD that aids secretion of the IgA, a portion of the IgA receptor on the plasmalemma of the inner side of the epithelial cells lining the gut, which is proteolysed when the IgA receptor complex has travelled through the cell after receptor mediated endocytosis at the inner face, to the outer (luminal) face.
(18 Nov 1997)
serum amyloid P component Precursor of amyloid component P, found in basement membrane. Member of the pentraxin family.
See: serum amyloid.
(18 Nov 1997)
two-component plasma <radiobiology> Refers to a plasma containing a cool thermal component and a population of high energy particles (such as from neutral beam injection) which are in the process of thermalising (slowing down).
(09 Oct 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • principal post
    Å« ±âµÕ;µ¿·®
  • principal rafter
    ÇÕ°¢
  • principal sentence
    ÁÖ¹®
  • principal sum
    (ÁöºÒµÇ´Â º¸Çè±ÝÀÇ)ÃÖ°í¾×
  • analysis
    ºÐÇØ
  • analysis
    ºÐ¼®;ÇØ¼®;ºÐÇØ
  • conformational analysis
    ¹èÁÂ ÇØ¼®
  • content analysis
    ³»¿ë ºÐ¼®
  • critical path analysis (method)
    Å©¸®Æ¼Äà ÆÐ½º ºÐ¼®¹ý(ÇÁ·ÎÁ§Æ®ÀÇ °èȹ.°ü¸®¸¦ °úÇÐÀûÀ¸·Î ÇÏ´Â ¹æ¹ý)
  • dream analysis
    ²Þ ºÐ¼®
  • factor analysis
    ÀÎÀÚ ºÐ¼®
  • harmonic analysis
    Á¶È­ ºÐ¼®;Á¶È­ ÇØ¼®;Á¶ÆÄ ºÐ¼®
  • high analysis
    (ºñ·á°¡)½Ä¹°ÀÇ ÇÊ¿ä ¾çºÐÀÇ 20% ÀÌ»óÀ» ÇÔÀ¯ÇÏ´Â
  • inputoutput analysis
    ÅõÀÔ»êÃâºÐ¼®
  • job analysis
    ÀÛ¾÷ ºÐ¼®
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á